FIDELIO BLOCK-CKD Dr. Bakris (Chicago) скачать в хорошем качестве

FIDELIO BLOCK-CKD Dr. Bakris (Chicago)

Dr. George Bakris discusses the background and the clinical implications of his FIDELIO and BLOCK-CKD trials, which studied novel mineralocorticoid receptor antagonists (Finerenone and KBP-5074) in patients with chronic kidney disease (FIDELIO and FIGARO) and with hypertension (BLOCK-CKD). Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes G.L. Bakris et al., N Engl J Med, 2020 https://www.nejm.org/doi/full/10.1056... Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study G.L. Bakris et al., Hypertension, 2021 https://www.ahajournals.org/doi/10.11... KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease https://kdigo.org/wp-content/uploads/... Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine R. Agarwal et al., Eur Heart J, 2021 https://academic.oup.com/eurheartj/ar... Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage P Kolkhof et al., Am J Nephrol, 2021 https://www.karger.com/Article/FullTe... SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection LY Herat et al., J Am Coll Cardiol Basic Trans Science, 2020 https://www.jacc.org/doi/full/10.1016... Effects of Canagliflozin in Patients with Baseline eGFR under 30 ml/min per 1.73 m2 Subgroup Analysis of the Randomized CREDENCE Trial G Bakris et al., Clin J Am Soc Nephrol, 2020 https://cjasn.asnjournals.org/content...